The company's proprietary technology, Pulse Controlled Amplification (PCA), offers a cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. This technology is being developed for infectious diseases and biothreats, and in collaboration with partners around the world, is taking molecular testing to new places. The company's vision is to make molecular testing accessible to everyone, everywhere.